This early-stage study is testing a one-time gene therapy injection for people with wet age-related macular degeneration (AMD), a leading cause of vision loss in older adults. The goal is to see if this single treatment can safely help control the disease and reduce the need for …
Phase: PHASE1, PHASE2 • Sponsor: Elisigen, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC